MetaCap

Omeros (OMER) vs Seaport Therapeutics (SPTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Omeros is the larger company by market cap ($983.7 million vs $966.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OMER-12.28%SPTX-9.02%
+44%-1%-47%
May 1, 20261 yearNov 20, 2026
OMER-12.28%SPTX-9.02%
+37%-5%-46%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OMER versus SPTX key metrics
MetricOMERSPTX
Share price$13.21$18.05
Market cap$983.66M$966.23M
1-day change-5.71%-1.47%
YTD return-23.11%—
1-year return+48.93%—
5-year return+77.79%—
P/E ratio (TTM)15.92—
Forward P/E11.95—
EPS (TTM)$0.83$-4.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-3.35M—
52-week high$21.24$28.38
52-week low$6.70$14.85
Distance from 52-week high-37.81%-36.40%
Analyst consensusbuystrong_buy
Avg. price target upside+108.18%+105.71%
Average volume1.36M259.83K
Shares outstanding74.46M53.53M
Employees17559
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

About Seaport Therapeutics

SPTX stock →

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

OMER vs SPTX FAQ

Which is bigger, Omeros or Seaport Therapeutics?

Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $966.23M for Seaport Therapeutics (SPTX).

Are Omeros and Seaport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons